Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting
Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients
Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…Abstract Number: 136 • 2017 ACR/ARHP Annual Meeting
Prevalence of Rheumatoid Arthritis and Associated Comorbidities in the 2011-2015 Medicare Population
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting about 1.5 million adults in the US (Helmick et al., 2008). Patients with RA have…Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…Abstract Number: 128 • 2016 ACR/ARHP Annual Meeting
Call to Action: Cardiovascular Comorbidities in Medicare Rheumatology Beneficiaries
Background/Purpose: Cardiovascular (CV) manifestations of Rheumatological inflammatory diseases have become increasingly recognized, and, in some patients, might even constitute the initial presentation of a Rheumatological…Abstract Number: 145 • 2016 ACR/ARHP Annual Meeting
Reduction in Musculoskeletal Ultrasound (MSK-US) Payments in 2014: Effects & Consequences
Background/Purpose: Rapid rise in the use of diagnostic and interventional MSK-US within the Medicare population between 2011 and 2013 has been documented amongst non-radiology…Abstract Number: 1255 • 2016 ACR/ARHP Annual Meeting
Medicare Part B Utilization By Rheumatology Health Care Providers As Related to Population Demographics from 2013
Background/Purpose: In 2015, the Center for Medicare and Medicaid Services released claims data on payments to over 950,000 health care providers paid through Medicare Part…Abstract Number: 925 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound (MSK-US): Innovation or Overutilization?
Background/Purpose: MSK-US use has risen in the USA with recent disturbing findings suggesting greater utilization of interventional ultrasound by non-noradiologists compared to Radiologists. (1) This…Abstract Number: 1268 • 2015 ACR/ARHP Annual Meeting
Utilization of Viscosupplementation: 2011 – 2013
Background/Purpose: Viscosupplementation (VS) is approved in the USA as an option for knee osteoarthritis (OA) pain. Recent American Academy of Orthopedic Surgeons (AAOS) guidelines have…Abstract Number: 1910 • 2014 ACR/ARHP Annual Meeting
Risk of Hypersensitiviy Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics
Background/Purpose: Healthcare providers have been alerted to the potential drug hypersensitivity reactions (HSRs, an adverse drug reaction that are uncommon but may be severe and…Abstract Number: 1849 • 2014 ACR/ARHP Annual Meeting
Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients
Background/Purpose The introduction of biologics has greatly changed the treatment of psoriatic arthritis (PsA) and psoriasis (PsO). However, there are concerns regarding the risk of…Abstract Number: 1070 • 2014 ACR/ARHP Annual Meeting
Mortality Risk in Patients with Rheumatoid Arthritis Who Develop Non–Hodgkin′s Lymphoma
Background/Purpose Patients with rheumatoid arthritis (RA) have greater risk of non-Hodgkin lymphoma (NHL) than the general population. A previous two-center study suggested that the rates…Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study
Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…Abstract Number: 2338 • 2013 ACR/ARHP Annual Meeting
Biologic Switching Rates Among Patients With Rheumatoid Arthritis
Background/Purpose: Treatment guidelines for the management of RA recommend sequential use of biologic therapies, and the majority of patients switch from one anti-TNF agent to…Abstract Number: 1053 • 2013 ACR/ARHP Annual Meeting
Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients
Background/Purpose: It is unclear if the elevated risks of adverse events in rheumatoid arthritis (RA) patients are due to use of biologics or DMARDs, glucocorticoids…Abstract Number: 1054 • 2013 ACR/ARHP Annual Meeting
Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Background/Purpose: Methotrexate (MTX) is the most commonly used medication in rheumatoid arthritis (RA), although use of oral and subcutaneous (SQ) preparations in real-world settings has…